Michael Hehenberger

Nanomedicine (eBook, PDF)

Science, Business, and Impact

• Format: PDF

Produktbeschreibung

By covering the science, business, and societal impact of nanomedicine, this book makes a strong case for funding of basic research, for effective translation of scientific breakthroughs into clinical care of patients, and for close collaboration among all stakeholders in the healthcare ecosystem. It covers the underlying science and technology of

---

Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Produktdetails

• Verlag: Taylor & Francis
• Seitenzahl: 428
• Erscheinungstermin: 18. Juni 2015
• Englisch
• ISBN-13: 9789814613774
• Artikelnr.: 43978268

Autorenporträt

Dr. Michael Hehenberger is founder of HM NanoMed LLC, Connecticut, USA. He retired after a long career with IBM at the end of 2013. He earned a Dipl. Ing. in physics from the Technical University of Vienna, Austria, and obtained his Ph.D. and Dr. Sc. degrees in quantum chemistry from Uppsala University, Sweden, in 1975-79. He also spent two years at the University of Florida, Gainesville, USA, as visiting associate professor. In 1985, he joined IBM in Stockholm, Sweden, to initiate academic partnerships in computational biology, structural engineering, computer networks, and supercomputing. Throughout his IBM career that took him to European Headquarters in Paris, California (Almaden Research, San Jose), and New York, he has led collaborations with academic and global industrial life sciences organizations. The partnerships were based on the joint desire to extend the frontiers of computational chemistry and biology, information-based medicine, biopharmaceutical research, and nanomedicine. His efforts have been documented in over 40 publications and book chapters.

Inhaltsangabe

Dedication. Purpose. Table of Contents. Introduction. What is
Nanomedicine?. What is Translational Medicine?. What is Innovation?. What
is Intellectual Property?. From IP to IPO. What is Impact?. From Atoms to
Proteins. Atoms and Molecules. Atoms of Life. Molecules of Life. Proteins.
Genetics and DNA Sequencing. DNA and the Genetic Code. From DNA to Proteins
and Cells. History of Genetics. Molecular Basis of Genetics. DNA Sequencing
and the Human Genome Project. Sequencing Technologies. Chemical Sequencing.
Sanger Sequencing, NGS and the $1,000 Genome Challenge. Second Generation
DNA Sequencing. Third Generation DNA Sequencing. Fourth Generation DNA
Sequencing. Sequencing Data Analysis. Bioethics. Business Aspects of
Sequencing Technology and the Human Genome Project. Post Human Genome
Project: "Omics". Bio-Pharmaceutical R&D. Stages of Bio-Pharmaceutical Drug
Discovery and Clinical Development. Stage 1: Drug Discovery. Stage 2:
Pre-Clinical Research. Stages 3-4: Clinical Trials and FDA Review. The
Emerging Importance of "Biologics". Biomarkers and Stratified/Personalized
Medicine. The Past and Future of Bio-Pharmaceutical R&D. Semiconductors:
Progress through Collaboration. Life Sciences Industry: Exclusive IP Deals
and Limited Collaboration. IMI and AMP. Nanomedicine. Computers in
Nanomedicine. Biocompatible Nanoparticles and Targeted Drug Delivery.
Dendrimers. Liposomes. Targeted Drug Delivery. The Business of
Nanotherapeutics. Biomedical and Molecular Imaging. Nanodiagnostics.
Regenerative Medicine: Stem Cells, Gene Therapy, Immunotherapy. Impact of
Nanomedicine. The Gut Microbiome. Central Nervous System: Brain and Spinal
Cord. Cancer and Immunology. Cardiovascular Disease. Diabetes. Infectious
Disease. Tissue and Organ Transplantation. The Healthcare Ecosystem AND
BIOMEDICAL RESEARCH FUNDING. It's all about the Patient/Consumer. The
Future of Funding for Basic Biomedical and Translational Research. Public
Health and Global Health Economics. Global View of Healthcare Costs, Infant
Mortality and Life Expectancy. US Health Statistics. Conclusions.
Acknowledgments. References.